KRAS and pancreatic serous cystadenoma: There was a single case of cftDNA positivity (mutation in the KRAS G12/13 hotspot) in the OPN group, specifically in the plasma sample from a patient diagnosed with a pancreatic serous cystadenoma (however, the cftDNA level was extremely low—2.34 copies/mL with a MAF of 0.12%).